Piper Jaffray analysts David Amsellem and Sameer Singh believe Valeant’s valuation and recent rally is overly optimistic
Axial Biotherapeutics appointed gastroenterologist Alessio Fasano, MD, to its board of directors along with six others.
Researchers working with StemSynergy Therapeutics discovered a class of WNT inhibitors that block colorectal cancer growth with minimal gastrointestinal toxicity.
RedHill Biopharma announced all enrolled patients completed treatment for the phase II study of its irritable bowel syndrome with diarrhea drug.
The FDA approved Gilead Sciences’ Vosevi as a second line therapy for chronic hepatitis C.
More articles on gastroenterology:
GI center to know: Spokane Digestive Disease Center
Solutions for every setting — Gastroenterologist Dr. Michael DiMarino on the gMed™ suite
GI leader to know: Dr. Paul Craig of Valley Gastroenterology
